RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-15.48%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$504M
AUM Growth
+$504M
(-24%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-12.78%
Top 10 Holdings %
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10
Top Buys
| 1 |
Biogen
BIIB
|
$9.89M |
| 2 |
Alkermes
ALKS
|
$8.44M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$5.94M |
| 4 |
Gilead Sciences
GILD
|
$5.14M |
| 5 |
Incyte
INCY
|
$4.35M |
Top Sells
| 1 |
Perrigo
PRGO
|
$10.7M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
$9.01M |
| 3 |
Medtronic
MDT
|
$8.4M |
| 4 |
HNT
HEALTH NET INC
HNT
|
$8.35M |
| 5 |
UnitedHealth
UNH
|
$7.86M |
Sector Composition
| 1 | Healthcare | 93.13% |
| 2 | Financials | 1.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $16.8M | 3.34% | 121,000 +21,000 | +21% | +$2.92M |
|
|
2
Gilead Sciences
GILD
$140B
| $16.5M | 3.28% | 180,000 +56,000 | +45% | +$5.14M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.7M | 3.11% | 190,000 +72,000 | +61% | +$5.94M |
|
4
Pfizer
PFE
$141B
| $14.1M | 2.79% | 475,000 +37,000 | +8% | +$1.1M |
|
5
Eli Lilly
LLY
$657B
| $14M | 2.79% | 195,000 +49,000 | +34% | +$3.53M |
|
|
6
Alkermes
ALKS
$4.78B
| $13.8M | 2.75% | 405,000 +247,000 | +156% | +$8.44M |
|
|
7
Incyte
INCY
$16.5B
| $12.3M | 2.45% | 170,000 +60,000 | +55% | +$4.35M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $12M | 2.38% | 120,000 +16,000 | +15% | +$1.6M |
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $11.9M | 2.35% | 125,000 -95,000 | -43% | -$9.01M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $11.3M | 2.23% | 42,000 -13,000 | -24% | -$3.48M |
|
11
CVS Health
CVS
$92.8B
| $10.9M | 2.16% | 105,000 -75,000 | -42% | -$7.78M |
|
|
12
Medtronic
MDT
$119B
| $10.3M | 2.04% | 137,000 -112,000 | -45% | -$8.4M |
|
|
STJ
13
DELISTED
St Jude Medical
STJ
| $9.9M | 1.97% | 180,000 +5,000 | +3% | +$275K |
|
|
14
Biogen
BIIB
$19.4B
| $9.89M | 1.96% | +38,000 | New | +$9.89M |
|
15
Zimmer Biomet
ZBH
$21B
| $9.7M | 1.93% | 91,000 -16,000 | -15% | -$1.71M |
|
16
Cigna
CI
$80.3B
| $9.47M | 1.88% | 69,000 -18,000 | -21% | -$2.47M |
|
17
Bristol-Myers Squibb
BMY
$96B
| $9.07M | 1.8% | 142,000 -41,000 | -22% | -$2.62M |
|
18
Labcorp
LH
$23.1B
| $8.79M | 1.74% | 75,000 -6,000 | -7% | -$703K |
|
19
Centene
CNC
$14.3B
| $8.73M | 1.73% | 141,712 -7,288 | -5% | -$449K |
|
|
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
| $8.6M | 1.71% | 187,000 +27,000 | +17% | +$1.24M |
|
|
WBA
21
DELISTED
Walgreens Boots Alliance
WBA
| $8.42M | 1.67% | 100,000 -32,000 | -24% | -$2.7M |
|
22
HCA Healthcare
HCA
$94.5B
| $8.12M | 1.61% | 104,000 +8,000 | +8% | +$624K |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $7.85M | 1.56% | 125,000 +63,000 | +102% | +$3.95M |
|
|
24
Perrigo
PRGO
$3.27B
| $7.8M | 1.55% | 61,000 -84,000 | -58% | -$10.7M |
|
|
25
UnitedHealth
UNH
$281B
| $7.73M | 1.54% | 60,000 -61,000 | -50% | -$7.86M |
|